Tuesday, 6 March 2012

Capsicum


Pronunciation: Not applicable.
Generic Name: Capsicum
Brand Name: ( Capsicum) Cayenne


Capsicum is used for:

Upset stomach, cold symptoms, pain treatments, and to improve circulation. It may also have other uses. Check with your pharmacist for more details regarding the particular brand you use.


Capsicum is an herbal product. It works by acting on the nerves to temporarily relieve pain sensations.


Do NOT use Capsicum if:


  • you are allergic to any ingredient in Capsicum

Contact your doctor or health care provider right away if any of these apply to you.



Before using Capsicum:


Some medical conditions may interact with Capsicum. Tell your doctor or pharmacist if you have any medical conditions, especially if any of the following apply to you:


  • if you are pregnant, planning to become pregnant, or are breast-feeding

  • if you are taking any prescription or nonprescription medicine, herbal preparation, or dietary supplement

  • if you have allergies to medicines, foods, or other substances (especially latex, bananas, kiwi, chestnut, avocado)

  • if you have ulcers or other stomach or bowel problems, or mugwort-celery-spice syndrome

Some MEDICINES MAY INTERACT with Capsicum. However, no specific interactions are known at this time.


This may not be a complete list of all interactions that may occur. Ask your health care provider if Capsicum may interact with other medicines that you take. Check with your health care provider before you start, stop, or change the dose of any medicine.


How to use Capsicum:


Use Capsicum as directed by your doctor. Check the label on the medicine for exact dosing instructions.


  • Dosing depends on the use and the source of the product.

  • Use as directed on the package, unless instructed otherwise by your doctor.

  • If you miss taking a dose of Capsicum for 1 or more days, there is no cause for concern. If your doctor recommended that you take it, try to remember your dose every day.

Ask your health care provider any questions you may have about how to use Capsicum.



Important safety information:


  • Capsicum is not recommended for use in young CHILDREN.

  • PREGNANCY and BREAST-FEEDING: Use of Capsicum is not recommended if you are pregnant. Consult your doctor before using this product. If you are or will be breast-feeding while you are using this product, check with your doctor or pharmacist to discuss the risks to your baby.


Possible side effects of Capsicum:


All medicines may cause side effects, but many people have no, or minor, side effects. Check with your doctor if any of these most COMMON side effects persist or become bothersome:



Burning in the mouth and throat; cough; runny nose; stomach pain; stomach upset.



Seek medical attention right away if any of these SEVERE side effects occur:

Severe allergic reactions (rash; hives; itching; difficulty breathing; tightness in the chest; swelling of the mouth, face, lips, or tongue).



This is not a complete list of all side effects that may occur. If you have questions about side effects, contact your health care provider. Call your doctor for medical advice about side effects. To report side effects to the appropriate agency, please read the Guide to Reporting Problems to FDA.


See also: Capsicum side effects (in more detail)


If OVERDOSE is suspected:


Contact 1-800-222-1222 (the American Association of Poison Control Centers), your local poison control center, or emergency room immediately.


Proper storage of Capsicum:

Store at room temperature away from heat, moisture, and light unless otherwise directed on the package label. Do not store in the bathroom. Most herbal products are not in childproof containers. Keep Capsicum out of the reach of children and away from pets.


General information:


  • If you have any questions about Capsicum, please talk with your doctor, pharmacist, or other health care provider.

  • Capsicum is to be used only by the patient for whom it is prescribed. Do not share it with other people.

  • If your symptoms do not improve or if they become worse, check with your doctor.

  • Check with your pharmacist about how to dispose of unused medicine.

This information is a summary only. It does not contain all information about Capsicum. If you have questions about the medicine you are taking or would like more information, check with your doctor, pharmacist, or other health care provider.



Issue Date: February 1, 2012

Database Edition 12.1.1.002

Copyright © 2012 Wolters Kluwer Health, Inc.

More Capsicum resources


  • Capsicum Side Effects (in more detail)
  • Capsicum Use in Pregnancy & Breastfeeding
  • Capsicum Drug Interactions
  • Capsicum Support Group
  • 0 Reviews for Capsicum - Add your own review/rating


Compare Capsicum with other medications


  • Coronary Artery Disease
  • Heart Disease
  • Herbal Supplementation
  • Infectious Gastroenteritis
  • Tonsillitis/Pharyngitis

Friday, 2 March 2012

Brexidol 20mg tablets





1. Name Of The Medicinal Product



BREXIDOL 20 mg Tablets


2. Qualitative And Quantitative Composition



Each tablet contains 20 mg piroxicam (as βetadex)



For excipients see section 6.1



3. Pharmaceutical Form



Tablet



Pale yellow, hexagonal tablet with a median score line on one side



4. Clinical Particulars



4.1 Therapeutic Indications



Piroxicam is indicated for symptomatic relief of osteoarthritis, rheumatoid arthritis or ankylosing spondylitis.



Due to its safety profile (see sections 4.2, 4.3 and 4.4), piroxicam is not a first line option should an NSAID be indicated. The decision to prescribe piroxicam should be based on an assessment of the individual patient's overall risks (see sections 4.3 and 4.4).



4.2 Posology And Method Of Administration



Route of Administration



For oral use



Two equivalent halves of a tablet (10 mg as piroxicam), are obtained by placing the tablet on a hard surface, with the score fracture line upwards and pressing it in half using the thumb.



Dosage Recommendations



Adults



The prescription of piroxicam should be initiated by physicians with experience in the diagnostic evaluation and treatment of patients with inflammatory or degenerative rheumatic diseases.



The maximum recommended daily dose is 20 mg, administered as one single daily dose, preferably with or after food.



Undesirable effects may be minimised by using the minimum effective dose for the shortest duration necessary to control symptoms (see section 4.4). The benefit and tolerability of treatment should be reviewed within 14 days. If continued treatment is considered necessary, this should be accompanied by frequent review.



Given that piroxicam has been shown to be associated with an increased risk of gastrointestinal complications, the possible need for combination therapy with gastro-protective agents (e.g. misoprostol or proton pump inhibitors) should be carefully considered, in particular for elderly patients.



Children



The use of piroxicam in children is not recommended.



The Elderly



In elderly patients, it may be necessary to reduce the dosage (half a tablet), and limit the duration of treatment. Again, it is preferable to take the dose with or after food.



NSAIDs should be used with particular caution in elderly patients who are more prone to adverse events.



4.3 Contraindications



- known hypersensitivity to any of the constituents or piroxicam



- history of gastro-intestinal ulceration, bleeding or perforation



- patient history of gastrointestinal disorders that predispose to bleeding disorders such as ulcerative colitis, Crohn's disease, gastrointestinal cancers or diverticulitis



- patients with active peptic ulcer, inflammatory gastrointestinal disorder or gastrointestinal bleeding



- concomitant use with other NSAIDs, including COX-2 selective NSAIDs and acetylsalicylic acid at analgesic doses



- concomitant use with anticoagulants



- history of previous serious allergic drug reaction of any type, especially cutaneous reactions such as erythema multiforme, Stevens-Johnson syndrome, toxic epidermal necrolysis



- hypersensitivity to the active substance, previous skin reaction (regardless of severity) to piroxicam, other NSAIDs and other medications



- porphyria



- severe heart failure



Brexidol is contra-indicated in children.



4.4 Special Warnings And Precautions For Use



Undesirable effects may be minimised by using the minimum effective dose for the shortest duration necessary to control symptoms (see section 4.2).



The clinical benefit and tolerability should be re-evaluated periodically and treatment should be immediately discontinued at the first appearance of cutaneous reactions or relevant gastrointestinal events.



Gastrointestinal (GI) Effects, Risk of GI Ulceration, Bleeding and Perforation



NSAIDs, including piroxicam, can cause serious gastrointestinal events including bleeding, ulceration, and perforation of the stomach, small intestine or large intestine, which can be fatal. These serious adverse events can occur at any time, with or without warning symptoms, in patients treated with NSAIDs.



NSAID exposures of both short and long duration have an increased risk of serious GI event. Evidence from observational studies suggests that piroxicam may be associated with a high risk of serious gastrointestinal toxicity, relative to other NSAIDs.



Patients with significant risk factors for serious GI events should be treated with piroxicam only after careful consideration (see sections 4.3 and below).



The possible need for combination therapy with gastro-protective agents (e.g. misoprostol or proton pump inhibitors) should be carefully considered (see section 4.2).



Serious GI Complications



Identification of at-risk subjects



The risk of developing serious GI complications increases with age. Age over 70 years is associated with high risk of complications. The administration to patients older than 80 years should be avoided.



Patients taking concomitant oral corticosteroids, selective serotonin reuptake inhibitors (SSRIs) or anti-platelet agents such as low-dose acetylsalicylic acid are at increased risk of serious GI complications (see below and section 4.5). As with other NSAIDs, the use of piroxicam in combination with protective agents (e.g. misoprostol or proton pump inhibitors) must be considered for these at-risk patients.



Patients and physicians should remain alerted for signs and symptoms of GI ulceration and/or bleeding during piroxicam treatment. Patients should be asked to report any new or unusual abdominal symptom during treatment. If a gastrointestinal complication is suspected during treatment, piroxicam should be discontinued immediately and additional clinical evaluation and treatment should be considered.



Cardiovascular and cerebrovascular effects



Appropriate monitoring and advice are required for patients with a history of hypertension and/or mild to moderate congestive heart failure as fluid retention and oedema have been reported in association with NSAID therapy.



Clinical trial and epidemiological data suggest that use of some NSAIDs (particularly at high doses and in long term treatment) may be associated with a small increased risk of arterial thrombotic events (for example myocardial infarction or stroke). There are insufficient data to exclude such a risk for piroxicam.



Patients with uncontrolled hypertension, congestive heart failure, established ischaemic heart disease, peripheral arterial disease, and/or cerebrovascular disease should only be treated with piroxicam after careful consideration.



Similar consideration should be made before initiating longer-term treatment of patients with risk factors for cardiovascular disease (e.g. hypertension, hyperlipidaemia, diabetes mellitus, smoking).



To avoid the risk of increased side effects, piroxicam should not be given with other non-steroidal anti-inflammatory agents.



In patients with renal, cardiac or hepatic impairment, caution is required since the use of NSAIDs may result in deterioration of renal function. Assessment of renal function in such patients, should occur prior to the initiation of therapy and regularly thereafter.



Piroxicam may cause a decrease in platelet aggregation and prolongation of bleeding time. This effect should be kept in mind when bleeding times are determined.



As NSAIDs can interfere with platelet function, they should be used with caution in patients with intracranial haemorrhage and bleeding diathesis.



Caution is required if piroxicam is administered to patients suffering from or with a previous history of bronchial asthma since NSAIDs have been reported to cause bronchospasm in such patients.



There are reports of reversible elevation of blood urea, nitrogen and creatinine.



In rare cases, NSAIDs may cause interstitial nephritis, glomerulitis papillary necrosis and nephrotic syndrome. They inhibit synthesis of renal prostaglandin that plays a supportive role in maintaining renal perfusion in patients with reduced blood volume and renal blood flow. In such patients, administration of a NSAID may precipitate overt renal decompensation, which is followed by recovery to the pre



Skin reactions



Serious skin reactions, some of them fatal, including exfoliative dermatitis, Stevens-Johnson syndrome, and toxic epidermal necrolysis, have been reported very rarely in association with the use of NSAIDs (see section 4.8). Evidence from observational studies suggests that piroxicam may be associated with a higher risk of serious skin reactions than other non-oxicam NSAIDs. Patients appear to be at highest risk of these reactions early in the course of therapy, the onset of the reaction occurring in the majority of cases within the first month of treatment. Piroxicam should be discontinued at the first appearance of skin rash, mucosal lesions, or any other signs of hypersensitivity.



4.5 Interaction With Other Medicinal Products And Other Forms Of Interaction



Care should be taken in patients treated with any of the drugs mentioned below because, as with other NSAIDs, piroxicam has the potential to induce the following interactions.



Other Analgesics



As with other NSAIDs, the use of piroxicam together with acetylsalicylic acid or concomitant use with other NSAIDs, including other piroxicam formulations, must be avoided, since data are inadequate to show that such combinations produce greater improvement than that achieved with piroxicam alone; moreover, the potential for adverse reactions is enhanced (see section 4.4). Human studies have shown that concomitant use of piroxicam and acetylsalicylic acid reduces the plasma piroxicam concentration to about 80% of the usual value.



Anti-hypertensives



There may be a reduction in the effect of anti-hypertensives.



Diuretics



Piroxicam may cause sodium, potassium and fluid retention, and may interfere with the natriuretic action of diuretic drugs causing a reduction in the diuretic effect. Diuretics can increase the risk of nephrotoxicity of NSAIDs. These properties should be kept in mind when treating patients with compromised cardiac function or hypertension, to avoid a possible worsening of these conditions.



Cardiac Glycosides



NSAIDs may exacerbate cardiac failure, reduce GFR and increase plasma cardiac glycosides levels.



Concomitant administration of antacids had no effect on piroxicam plasma levels, nor did concurrent therapy of piroxicam with digoxin or digitoxin affect the plasma levels of either drug.



Sulphonamides and Hydantoins



Piroxicam is highly protein bound, and therefore, it might be expected to displace other protein bound drugs e.g. anticoagulants, sulphonamides and hydantoins such as phenytoin. Patients must be monitored closely for change in dosage requirements when giving Brexidol to patients already receiving other highly protein bound drugs.



Anticoagulants



NSAIDs, including piroxicam, may enhance the effects of anti-coagulants, such as warfarin. Therefore, the use of piroxicam with concomitant anticoagulant such as warfarin should be avoided (see section 4.3)..



Anti-platelet agents and selective serotonin reuptake inhibitors (SSRIs)



Increased risk of gastrointestinal bleeding (see section 4.4).



Cimetidine



There is some evidence that a slight but significant increase in absorption of piroxicam may occur following administration of cimetidine



Lithium



NSAIDs, including piroxicam, have been reported to decrease the elimination of lithium. It is recommended that the levels of lithium are monitored when initiating, adjusting or discontinuing treatment with piroxicam.



Quinolone Antibiotics



Animal data indicate that NSAIDs can increase the risk of convulsions associated with quinolone antibiotics. Patients taking NSAIDs and quinolones may have an increased risk of developing convulsions.



Mifepristone



In common with other NSAIDs, piroxicam should be avoided for at least 8 to 12 days following mifepristone administration as NSAIDs can reduce the effect of mifepristone.



Methotrexate



There is decreased elimination of methotrexate with NSAIDs.



Ciclosporin



NSAIDs may increase ciclosporin nephrotoxicity as a result of their effect on renal prostaglandins.



Corticosteroids



Increased risk of gastrointestinal ulceration or bleeding (see section 4.4).



Aminoglycosides



Reduction in renal function in susceptible individuals, decreased elimination of aminoglycosides and increased plasma concentrations have been reported.



Probenecid



Reduction in metabolism and elimination of NSAID and metabolites occurs with probenecid.



Oral Hypoglycaemic Agents



Inhibition of metabolism of sulfonylurea drugs, prolonged half-life and increased risk of hypoglycaemia is known to occur with oral hypoglycaemic agents.



4.6 Pregnancy And Lactation



Although no teratogenic effects have been demonstrated in animal toxicology studies, the use of NSAIDs during pregnancy should, if possible, be avoided.



Congenital abnormalities have been reported in association with NSAID administration in man. However, these are low in frequency and do not appear to follow any discernible pattern.



Piroxicam inhibits prostaglandin synthesis and release through a reversible inhibition of the cyclo



A study indicates that piroxicam is found in breast milk at about 1 % to 3 % of the maternal plasma concentrations. No accumulation of piroxicam occurred in milk relative to that in plasma during treatment for up to 52 days. Brexidol is not recommended for use in nursing mothers because clinical safety in neonates has not been established.



4.7 Effects On Ability To Drive And Use Machines



Piroxicam can alter the state of alertness to such an extent that driving vehicles or performing activities which require quick reflexes (such as operating machinery), may be affected.



Since swollen eyes, blurred vision and eye irritation have been reported in association with the use of piroxicam, and dizziness, drowsiness or headaches are possible side effects associated with taking NSAIDs, patients should be warned to take care when undertaking such activities.



Although routine ophthalmology and slit



4.8 Undesirable Effects



Gastrointestinal



Gastrointestinal symptoms associated with piroxicam administration are the most common side effects, but in most cases do not interfere with continuation of therapy. These include ulcerative stomatitis, anorexia, epigastric or abdominal discomfort or pain, nausea, constipation, flatulence, diarrhoea and indigestion, vomiting, dyspepsia, melaena and haematemesis.



Gastric ulceration, duodenal ulcer and gastrointestinal perforation and gastrointestinal bleeding, in rare cases fatal, have been reported with piroxicam. Long



Hypersensitivity Reactions



There are rare reports of piroxicam causing cutaneous hypersensitivity reactions such as rash or pruritus, urticaria, angioedema, onycholysis or alopecia. As with other NSAIDs, epidermal necrolysis (Lyell's disease), Stevens



These reactions may also consist of respiratory tract reactivity comprising of asthma, aggravated asthma, bronchospasm or dyspnoea.



There may be other non-specific allergic reactions and anaphylaxis.



Other hypersensitivity reactions such as vasculitis and serum sickness have been rarely reported.



Dermatological Reaction



Photosensitivity reactions occur infrequently.



Renal



Rarely, NSAIDs may cause interstitial nephritis, glomerulo



Haematological Reactions



Decreases in haemoglobin and haematocrit in the absence of obvious gastrointestinal bleeding have occurred and anaemia has been reported, as have thrombocytopenia, non



Hepatic



Changes in various liver function parameters have been seen with piroxicam and, as with other NSAIDs, some patients may show an increase in serum transaminase concentration during piroxicam treatment; also, severe hepatic reactions, including jaundice and cases of fatal hepatitis have also occurred.



Even though such events are rare, where abnormal liver function tests persist or worsen or clinical signs consistent with liver disease develop, or there are systemic manifestations (such as a rash or eosinophilia), treatment should be discontinued.



Cardiovascular



Oedema, hypertension, and cardiac failure, have been reported in association with NSAID treatment.



Equally, elderly, frail or debilitated patients require careful supervision because they may tolerate side effects less well; the elderly require caution since they are more likely to have impaired renal, hepatic or cardiac function.



Clinical trial and epidemiological data suggest that use of some NSAIDs (particularly at high doses and in long term treatment) may be associated with an increased risk of arterial thrombotic events (for example myocardial infarction or stroke) (see section 4.4).



Neurological and Special Senses



CNS effects including dizziness, headache, somnolence, insomnia, depression, nervousness, hallucinations, mood alterations, dream abnormalities, mental confusion, paraesthesias, vertigo, visual disturbances, optic neuritis, tinnitus, malaise, fatigue and drowsiness have all been reported.



Palpitations, metabolic abnormalities such as hypoglycaemia, weight increase or decrease and anecdotal cases of positive ANA or hearing impairment have all been reported.



4.9 Overdose



Symptoms



The most likely symptoms of overdose are headache, vomiting, drowsiness, dizziness and fainting.



Management



In the event of an overdose with Brexidol, supportive and symptomatic management is necessary and may include gastric lavage and the use of oral activated charcoal to reduce absorption of piroxicam. The correction of severe electrolyte abnormalities may need to be considered.



5. Pharmacological Properties



5.1 Pharmacodynamic Properties



Brexidol is an inclusion complex of piroxicam and βeta



The faster dissolution characteristics of piroxicam βetadex (about 100% in 10 minutes) with respect to piroxicam alone, results in a quicker absorption of the active ingredient and promotes a more rapid onset of analgesic action (see Pharmacokinetics).



5.2 Pharmacokinetic Properties



As a NSAID, piroxicam is well absorbed after oral administration and is extensively metabolised by the liver with elimination occurring via the kidneys.



The drug has a plasma half-life of about 50 hours with the maintenance of plasma levels for up to 24 hours. Steady state levels are reached in 7 to 12 days and maintained with little change for up to a year of treatment.



The absorption of piroxicam from piroxicam βetadex is more rapid than that of piroxicam alone, so that the time taken to reach the maximum plasma concentration (Tmax), is much shorter; clinically this is reflected by a more rapid onset of acute analgesia after single doses.



Studies on healthy volunteers demonstrated that, after single oral administration at equivalent doses (20 mg as piroxicam), piroxicam from piroxicam βetadex was absorbed at least 2 times faster than it was as the plain drug. The maximum plasma concentration (Cmax) of piroxicam was reached within 30 to 60 minutes with piroxicam βetadex and was higher than that obtained after 2 hours with plain piroxicam.



5.3 Preclinical Safety Data



Preclinical data reveal no special hazard for humans based on conventional studies of safety pharmacology, repeated dose toxicology, genotoxicology and toxicology of reproduction.



6. Pharmaceutical Particulars



6.1 List Of Excipients



Lactose monohydrate



Crospovidone



Sodium starch glycollate



Colloidal silicon dioxide



Pregelatinised starch



Magnesium stearate



6.2 Incompatibilities



Not applicable



6.3 Shelf Life



36 months



6.4 Special Precautions For Storage



No special precautions for storage



6.5 Nature And Contents Of Container



The tablets are enclosed in opaque blisters composed of 250 µm PVC coated with 40 g m-2 PVDC and 25 µm aluminium coated with 18 to 20 g m-2 PVDC.



The blisters are boxed in cardboard cartons containing 2, 5, 7 or 30 tablets and a user leaflet.



6.6 Special Precautions For Disposal And Other Handling



Not applicable



7. Marketing Authorisation Holder



Chiesi Limited



Cheadle Royal Business Park



Highfield



Cheadle



SK8 3GY



United Kingdom



8. Marketing Authorisation Number(S)



PL 08829/0104



9. Date Of First Authorisation/Renewal Of The Authorisation



8th January 2002



10. Date Of Revision Of The Text



08 /01/2009



11. Legal Category


POM




Wednesday, 29 February 2012

HT-Tuss DM Elixir



dextromethorphan hydrobromide and guaifenesin

Dosage Form: elixir
HT-Tuss DM Elixir

HT-Tuss DM Elixir Description


Each 5 mL (one teaspoonful) of HT-Tuss DM Elixir contains:


Dextromethorphan hydrobromide . . . 20 mg


Guaifenesin . . . . 200 mg


Alcohol . . . . . . . . . . . 5%


Also contains: Citric acid, FD&C blue #1, FD&C red #3, FD&C red #40, high fructose corn syrup, natural & artificial grape flavor, propylene glycol, purified water, saccharin sodium, sodium benzoate. Sodium citrate may be used to adjust pH.


Dextromethorphan hydrobromide, a synthetic monopioid antitussive, is a salt of the methyl ether of the dextrorotatory isomer of levorphanol, an opioid analgesic. The chemical name is 3- methoxy-17-methyl-9α, 13α, 14α-morphinan hydrobromide monohydrate. It has the following structural formula:



Guaifenesin is an expectorant. The chemical name is (±)-3-(o- Methoxyphenoxy)-1,2- propanediol. It has the following structural formula:




HT-Tuss DM Elixir - Clinical Pharmacology


HT-Tuss DM Elixir combines the cough suppressant dextromethorphan hydrobromide and the expectorant guaifenesin.


Dextromethorphan hydrobromide is a non-opioid antitussive agent. Dextromethorphan temporarily controls and suppresses the cough reflex by a direct action on the cough center. It has no significant analgesic or sedative properties, does not depress respiration or predispose to addiction with usual doses. In therapeutic dosage, dextromethorphan does not inhibit ciliary activity.


Dextromethorphan is rapidly absorbed from the gastrointestinal tract and exerts its effect 15-30 minutes after oral administration. The duration of action is approximately 3-6 hours. Dextromethorphan is rapidly and extensively metabolized by the liver. It is primarily renally excreted as unchanged dextromethorphan and demethylated metabolites including dextrorphan, an active metabolite.


Guaifenesin is an expectorant. Expectorants promote and facilitate the removal of respiratory tract secretions. By increasing respiratory tract fluid, guaifenesin reduces the viscosity of secretions, and facilitates expectoration of retained secretions. Guaifenesin is readily absorbed from the gastrointestinal tract and is rapidly metabolized and renally excreted. Guaifenesin has a plasma half-life of one hour. The major urinary metabolite is beta-(2-methoxyphenoxy) lactic acid.



Indications and Usage for HT-Tuss DM Elixir


HT-Tuss DM Elixir temporarily relieves coughs due to minor throat and bronchial irritation as may occur with upper respiratory tract infections or inhaled irritants, when complicated by viscous mucus. Dextromethorphan hydrobromide suppresses the cough control center and relieves coughing. Guaifenesin helps loosen phlegm (mucus) and thin bronchial secretions to rid the bronchial passageways of bothersome mucus, drain bronchial tubes, and make coughs more productive.



Contraindications


HT-Tuss DM Elixir is contraindicated in patients hypersensitive to any of the ingredients and in patients receiving monoamine oxidase inhibitor (MAOI) therapy, including 14 days after stopping MAOI therapy (see PRECAUTIONS: Drug Interactions).



Warnings


A persistent cough may be a sign of a serious condition. If cough persists for more than one week or tends to recur, or is accompanied by fever, rash, or persistent headache, patient reevaluation should be considered.



Precautions



General


Before prescribing any medication to suppress or modify cough, it is important that the underlying cause of cough is identified, that modification of cough does not increase the risk of clinical or physiological complications, and that appropriate therapy for the primary disease is instituted.



Information for patients


Patients should be warned not to use this product If they are now taking a prescription monoamine oxidase inhibitor [MAOI] (certain drugs for depression, psychiatric or emotional conditions, or Parkinson’s disease), including 14 days after stopping the MAOI drug. If patients are uncertain whether a prescription drug contains an MAOI, they should be instructed to consult a health professional before taking this product.



Drug Interactions


Serious toxicity (serotonin syndrome) has been reported in patients receiving dextromethorphan hydrobromide and monoamine oxidase inhibitors [MAOIs] concomitantly. Dextromethorphan preparations should not be used in patients receiving MAOIs, including 14 days after stopping the MAOI drug. The use of dextromethorphan hydrobromide may result in additive CNS depressant effects when coadministered with alcohol, antihistamines, psychotropics or other drugs which produce CNS depression.



Laboratory Test Interactions


Guaifenesin interferes with the colorimetric determination of 5-HIAA (5-hydroxyindoleacetic acid) and VMA (vanillylmandelic acid).



Carcinogenesis, mutagenesis, impairment of fertility


No data are available on the long term potential of dextromethorphan hydrobromide or of guaifenesin for carcinogenesis, mutagenesis, or impairment of fertility in animals or humans.



Pregnancy


Teratogenic effects

Pregnancy Category C: Animal reproduction studies have not been conducted with dextromethorphan hydrobromide or guaifenesin. It is also not known whether dextromethorphan hydrobromide or guaifenesin can cause fetal harm when administered to a pregnant woman or can affect reproduction capacity. HT-Tuss DM Elixir should be given to a pregnant woman only if clearly needed.



Nursing mothers


It is not known whether dextromethorphan hydrobromide or guaifenesin is excreted in human milk. Because many drugs are excreted in human milk, caution should be exercised when dextromethorphan hydrobromide or guaifenesin are administered to a nursing woman.



Pediatric use


The safety and effectiveness of dextromethorphan hydrobromide and guaifenesin in pediatric patients have been established in the age groups 2 years to over 12 years. Safety and effectiveness in pediatric patients below the age of 2 years have not been established. (see DOSAGE AND ADMINISTRATION).


Administration of dextromethorphan may be associated with histamine release and should be used with caution in atopic children.



Adverse Reactions


Adverse effects associated with dextromethorphan hydrobromide are rare, but nausea and/or other gastrointestinal disturbances, slight dizziness and drowsiness sometimes occur (see also Drug Interactions). Guaifenesin is well tolerated and has a wide margin of safety. Adverse effects associated with guaifenesin usually result from doses larger than those required for expectoration. Reported adverse reactions include nausea and vomiting, dizziness, headache and rash (including urticaria).


To report SUSPECTED ADVERSE REACTIONS, contact Hi-Tech Pharmacal Co., Inc. at 1-800-262- 9010.



Overdosage


Overdosage with dextromethorphan hydrobromide may produce central excitement and mental confusion. Very high doses may produce respiratory depression. Overdosage with guaifenesin is unlikely to produce toxic effects since its toxicity is low. When laboratory animals were administered guaifenesin in doses up to 5 g/kg by stomach tube, no toxicity resulted.


In severe cases of overdosage, the stomach should be emptied (emesis or gastric lavage) and further absorption prevented. Treatment should be directed toward supporting the patient and reversing the effects of the drug.



HT-Tuss DM Elixir Dosage and Administration



Adults and children over 12 years of age:


One teaspoonful (5 mL) every 4 hours, not to exceed 6 teaspoonfuls in 24 hours.



Children 6-12 years:


One half (1.2) teaspoonful (2.5 mL) every 4 hours, not to exceed 3 teaspoonfuls in 24 hours.



Children 2-6 years:


One-fourth (1.4) teaspoonful (1.25 mL) every 4 hours, not to exceed 11.2 teaspoonfuls in 24 hours. It is recommended that caregivers obtain and use a calibrated measuring device for administering this product to a child. Use extreme care in measuring the dosage. Do not exceed the recommended daily dosage except under the advice and supervision of the prescribing physician.


KEEP OUT OF REACH OF CHILDREN.



How is HT-Tuss DM Elixir Supplied


HT-Tuss DM Elixir is a purple-colored, fruit-flavored liquid containing 20 mg dextromethorphan hydrobromide and 200 mg guaifenesin per 5 mL with 5% alcohol. It is supplied in containers of 1 pint (473 mL), NDC 50383-135-16.


Store at controlled room temperature, 15°-30°C (59°-86°F).


Rx Only






Manufactured by:


Hi-Tech Pharmacal Co. Inc.


Amityville, NY 11701




MG #13883


Rev. 135:01 3/09



PACKAGE/LABEL PRINCIPAL DISPLAY PANEL



NDC 50383-135-16


HT-Tuss DM Elixir


20 mg DEXTROMETHORPHANHYDROBROMIDE


AND


200 mg GUAIFENESIN


per 5 mL


Rx only


Each teaspoonful (5 mL) contains:


Dextromethorphan hydrobromide........................20 mg


Guaifenesin.........................................................200 mg


Alcohol.....................................................................5 %


USUAL DOSAGE: Adults and children over 12 years of age: one teaspoonful (5 mL) every 4 hours, not to exceed 6 teaspoonfuls in 24 hours. Children 6-12 years: one-half (½) teaspoonful (2.5 mL) every 4 hours, not to exceed 3 teaspoonfuls in 24 hours. Children 2-6 years: one-fourth (¼) teaspoonful (1.25 mL) every 4 hours, not to exceed 1½ teaspoonfuls in 24 hours.


See package insert for full prescribing information.


PHARMACIST: Dispense in a tight, light-resistant container with a child-resistant closure.


Store at controlled room temperature 15°-30°C (59°-86°F).


WARNING: Keep this and all medication out of reach of children.









HT-TUSS DM 
dextromethorphan hydrobromide and guaifenesin  elixir










Product Information
Product TypeHUMAN PRESCRIPTION DRUGNDC Product Code (Source)50383-135
Route of AdministrationORALDEA Schedule    











Active Ingredient/Active Moiety
Ingredient NameBasis of StrengthStrength
DEXTROMETHORPHAN HYDROBROMIDE (DEXTROMETHORPHAN)DEXTROMETHORPHAN HYDROBROMIDE20 mg  in 5 mL
GUAIFENESIN (GUAIFENESIN)GUAIFENESIN200 mg  in 5 mL




























Inactive Ingredients
Ingredient NameStrength
ALCOHOL 
ANHYDROUS CITRIC ACID 
FD&C BLUE NO. 1 
FD&C RED NO. 3 
FD&C RED NO. 40 
HIGH FRUCTOSE CORN SYRUP 
GRAPE 
PROPYLENE GLYCOL 
WATER 
SACCHARIN SODIUM 
SODIUM BENZOATE 
SODIUM CITRATE 


















Product Characteristics
Color    Score    
ShapeSize
FlavorImprint Code
Contains      










Packaging
#NDCPackage DescriptionMultilevel Packaging
150383-135-16473 mL In 1 BOTTLENone










Marketing Information
Marketing CategoryApplication Number or Monograph CitationMarketing Start DateMarketing End Date
Unapproved drug other12/03/200110/27/2011


Labeler - Hi-Tech Pharmacal Co., Inc. (101196749)
Revised: 10/2009Hi-Tech Pharmacal Co., Inc.

More HT-Tuss DM Elixir resources


  • HT-Tuss DM Elixir Side Effects (in more detail)
  • HT-Tuss DM Elixir Dosage
  • HT-Tuss DM Elixir Use in Pregnancy & Breastfeeding
  • HT-Tuss DM Elixir Drug Interactions
  • HT-Tuss DM Elixir Support Group
  • 0 Reviews for HT-Tuss DM - Add your own review/rating


Compare HT-Tuss DM Elixir with other medications


  • Cough
  • Expectoration

Havrix



hepatitis a vaccine

Dosage Form: injection, suspension
FULL PRESCRIBING INFORMATION

Indications and Usage for Havrix


Havrix® is indicated for active immunization against disease caused by hepatitis A virus (HAV) for persons equal to or older than 12 months of age. Primary immunization should be administered at least 2 weeks prior to expected exposure to HAV.



Havrix Dosage and Administration



Preparation for Administration


Shake vial or syringe well before withdrawal and use. Parenteral drug products should be inspected visually for particulate matter and discoloration prior to administration, whenever solution and container permit. If either of these conditions exists, the vaccine should not be administered. With thorough agitation, Havrix is a homogeneous, turbid, white suspension. Do not administer if it appears otherwise.



Recommended Dose and Schedule


Havrix should be administered by intramuscular injection only. Havrix should not be administered in the gluteal region; such injections may result in suboptimal response.


Children and Adolescents: Primary immunization for children and adolescents (12 months through 18 years of age) consists of a single 0.5-mL dose and a 0.5-mL booster dose administered anytime between 6 and 12 months later in order to ensure the highest antibody titers. The preferred sites for intramuscular injections are the anterolateral aspect of the thigh in infants and young children or the deltoid muscle of the upper arm in older children.


Adults: Primary immunization for adults consists of a single 1-mL dose and a 1-mL booster dose administered anytime between 6 and 12 months later in order to ensure the highest antibody titers. In adults, the injection should be given in the deltoid region.



Dosage Forms and Strengths


Havrix is a sterile suspension available in the following presentations:


  • 0.5 mL single-dose vials and prefilled TIP-LOK® syringes.

  • 1.0 mL single-dose vials and prefilled TIP-LOK® syringes.

[See Description (11) and How Supplied (16) for a listing of vaccine components.]



Contraindications


Severe allergic reaction (e.g., anaphylaxis) after a previous dose of any hepatitis A-containing vaccine, or to any component of Havrix, including neomycin, is a contraindication to administration of Havrix [see Description (11)].



Warnings and Precautions



Hypersensitivity


Havrix may cause severe allergic reaction.


 Havrix is available in vials and 2 types of prefilled syringes. One type of prefilled syringe has a tip cap which may contain natural rubber latex. The other type has a tip cap and a rubber plunger which contain dry natural latex rubber. Use of these syringes may cause allergic reactions in latex sensitive individuals. The vial stopper does not contain latex. [See How Supplied/Storage and Handling (16).]


Appropriate medical treatment and supervision must be available to manage possible anaphylactic reactions following administration of the vaccine [see Contraindications (4)].



Altered Immunocompetence


Immunocompromised persons may have a diminished immune response to Havrix, including individuals receiving immunosuppressant therapy.



Limitations of Vaccine Effectiveness


Hepatitis A virus has a relatively long incubation period (15 to 50 days). Havrix may not prevent hepatitis A infection in individuals who have an unrecognized hepatitis A infection at the time of vaccination. Additionally, it may not prevent infection in individuals who do not achieve protective antibody titers (although the lowest titer needed to confer protection has not been determined).



Adverse Reactions


The most common solicited adverse events were injection-site soreness (56% of adults and 21% of children) and headache (14% of adults and less than 9% of children).



Clinical Trials Experience


Because clinical trials are conducted under widely varying conditions, adverse reaction rates observed in the clinical trials of a vaccine cannot be directly compared to rates in the clinical trials of another vaccine, and may not reflect the rates observed in practice.


The safety of Havrix has been evaluated in 60 clinical trials involving approximately 32,900 individuals receiving doses ranging from 360 EL.U. to 1440 EL.U.


The frequency of solicited adverse events tended to decrease with successive doses of Havrix.


Of solicited adverse events in clinical trials, the most frequently reported by volunteers was injection-site soreness (56% of adults and 21% of children); however, less than 0.5% of soreness was reported as severe. Headache was reported by 14% of adults and less than 9% of children. Other solicited and unsolicited events occurring during clinical trials are listed below.


Incidence 1% to 10% of Injections: Metabolism and Nutrition Disorders: Anorexia.


Gastrointestinal Disorders: Nausea.


General Disorders and Administration Site Conditions: Fatigue, fever (>37.5°C), induration, redness, and swelling of the injection site; malaise.


Incidence <1% of Injections: Infections and Infestations: Pharyngitis, upper respiratory tract infections.


Blood and Lymphatic System Disorders: Lymphadenopathy.


Psychiatric Disorders: Insomnia.


Nervous System Disorders: Dysgeusia, hypertonia.


Eye Disorders: Photophobia.


Ear and Labyrinth Disorders: Vertigo.


Gastrointestinal Disorders: Abdominal pain, diarrhea, vomiting.


Skin and Subcutaneous Tissue Disorders: Pruritus, rash, urticaria.


Musculoskeletal and Connective Tissue Disorders: Arthralgia, myalgia.


General Disorders and Administration Site Conditions: Injection site hematoma.


Investigations: Creatine phosphokinase increased.


Outbreak Setting and a Field Efficacy Trial: Safety data were obtained from 2 additional sources in which large populations were vaccinated. In an outbreak setting in which 4,930 individuals were immunized with a single dose of either 720 EL.U. or 1440 EL.U. of Havrix, no serious adverse events due to vaccination were reported. Overall, less than 10% of vaccinees reported solicited general adverse events following the vaccine. The most common solicited local adverse reaction was pain at the injection site, reported in 22% (650/2,911) of subjects at 24 hours and decreasing to 2% (71/2,838) by 72 hours.


In a field efficacy trial, 19,037 children received the 360 EL.U. dose of Havrix. The most commonly reported adverse events by children from 2 selected schools following administration of Havrix were injection-site pain (10%, 68/719) and tenderness (8%, 58/719), following first doses of Havrix. Pain was slightly higher following the first dose of Havrix (10%) compared to the group who received the comparison vaccine ENGERIX-B® (6%) but was similar between vaccines following the second dose (6% for both groups). Likewise, tenderness was slightly higher following the first dose of Havrix (8%) compared to the group who received the comparison vaccine ENGERIX-B (5%) but was similar between vaccines following the second dose (4% for both groups). The large trial further allowed for analysis of rare adverse events, including hospitalization and death. No significant differences were found between the cohorts.


Havrix 720 EL.U./0.5 mL at 11 Months of Age and Older: In a US multicenter study, parents/guardians recorded local and general adverse events on diary cards for 4 days (Days 0 to 3) after vaccination [see Clinical Studies (14.2)]. In the 3 groups of children who received Havrix alone, safety data were available for 723 children who received 1,396 documented doses of Havrix. Additional safety data were available for 181 children who received Havrix coadministered with INFANRIX® (Diphtheria and Tetanus Toxoids and Acellular Pertussis Vaccine Adsorbed) (DTaP) and Haemophilus influenzae type b (Hib) conjugate vaccine (tetanus toxoid conjugate) (PRP-T) (Sanofi Pasteur SA).


The following ranges of solicited adverse event rates were observed among 3 groups of children that received their first dose of Havrix alone at between 11 and 25 months of age: Injection site pain in 15 to 21% of subjects, redness in 16 to 21% of subjects, swelling in 8% of subjects, irritability in 24 to 36% of subjects, loss of appetite in 16 to 19% of subjects, drowsiness in 15 to 17% of subjects and fever (>39.5°C) in ≤2% of subjects. Following the booster dose of Havrix, among local reactions: Pain was reported in 16 to 21% of subjects, redness in 17 to 22%, swelling in 8 to 10% of subjects. Following the booster dose of Havrix, among general events, irritability was reported in 19 to 29% of subjects, loss of appetite in 14 to 18% of subjects, drowsiness in 13 to 16% of subjects and fever (>39.5°C) in ≤1% of subjects.


Drowsiness and loss of appetite occurred at higher rates in subjects 15 to 18 months of age who received Hib conjugate vaccine and INFANRIX concomitantly with Havrix as compared to subjects 15 to 18 months of age who received Hib conjugate vaccine and INFANRIX (drowsiness 34% and 22% and loss of appetite 29% and 19%, respectively). With the exception of fever (>39.5°C), the solicited general symptoms occurred at higher rates in subjects 15 to 18 months of age who received Hib conjugate vaccine and INFANRIX concomitantly with Havrix as compared to subjects 15 to 18 months of age who received Havrix alone (irritability 46% and 30%, drowsiness 34% and 17%, and loss of appetite 29% and 17%, respectively).


A febrile seizure was reported in an 18-month-old subject 2 days after receiving the first dose of Havrix. Other serious adverse events reported during the course of this study with the use of Havrix alone included a single case each of hepatitis ~5 months post dose 1, insulin-dependent diabetes ~4 months post dose 1, and Kawasaki’s disease ~3½ months post dose 1. The association of these events with vaccination is unknown.


In an open-label, randomized, US multicenter study, children 15 months of age received the 2-dose series of Havrix. The second dose of Havrix was given 6 to 9 months after the first dose. One group received Havrix alone (n = 122); a second group received the first dose of Havrix coadministered with INFANRIX and Hib conjugate vaccine (PRP-T) (Sanofi Pasteur SA) (n = 129); and a third group received INFANRIX and Hib conjugate vaccine coadministered and the first dose of Havrix one month later (n = 115). [See Clinical Studies (14.5).] The percentages of subjects for whom solicited local adverse events (days 0 to 3) were reported following the first dose of Havrix alone, Havrix coadministered with INFANRIX and Hib conjugate, and coadministration of INFANRIX and Hib conjugate were as follows: Pain (21%, 45%, 40%), redness (15%, 42%, 42%) and swelling (8%, 30%, 30%). The percentages of subjects for whom solicited local symptoms at the Havrix injection site were reported after the first dose of Havrix in the Havrix alone group compared to subjects who received Havrix coadministered with INFANRIX and Hib conjugate vaccine were as follows: Pain (21% versus 35%), redness (15% versus 30%), and swelling (8% versus 16%).


Solicited general adverse events (days 0 to 3) reported among children following the first dose of Havrix alone, Havrix coadministered with INFANRIX and Hib conjugate vaccine, and coadministration of INFANRIX and Hib conjugate vaccine were as follows: Irritability (33%, 43%, 34%), drowsiness (25%, 34%, 24%), loss of appetite (16%, 24%, 17%), and fever [>38.0°C] (8%, 16%, 19%).


In this trial, 14 subjects reported 24 serious adverse events, including 6 subjects in the Havrix group (status asthmaticus, asthma [2 events], failure to thrive, gastroenteritis, arthritis bacterial, developmental delay, expressive language disorder, dehydration [3 events]), 3 subjects in the group who received Havrix coadministered with INFANRIX and Hib conjugate vaccine (dehydration, gastroenteritis rotavirus, gastroenteritis, pyrexia, tachycardia), and 5 subjects in the group that received the INFANRIX and Hib conjugate vaccine followed by Havrix (bronchial hyperreactivity, respiratory distress, developmental delay, expressive language disorder, dehydration [2 events], gastroenteritis rotavirus, tonsillar hypertrophy). All events were reported as recovered or recovering by the end of the study. No fatalities occurred.


In another US multicenter study, children 15 months of age (range 14 to 16 months) received either Havrix coadministered with a US-licensed pneumococcal 7-valent conjugate vaccine (Wyeth Pharmaceuticals Inc.) followed by a second dose of Havrix 6 to 9 months later; Havrix administered alone followed by a second dose of Havrix 6 to 9 months later; or pneumococcal 7-valent conjugate vaccine administered alone followed by a first dose of Havrix one month later and a second dose of Havrix 6 to 9 months after the first [see Clinical Studies (14.5)]. Parents/guardians recorded local and general symptoms on diary cards for 4 days (Days 0 to 3) after vaccination.


Solicited local adverse events were reported as follows among children who received the first dose of Havrix coadministered with pneumococcal 7-valent conjugate vaccine: Pain was reported in 36% of subjects, redness in 41% of subjects, and swelling in 29% of subjects. Reported rates of these local adverse events were similar to those in children who received the first dose of pneumococcal 7-valent conjugate vaccine alone (44%, 46%, and 27%, respectively). Among children who received the first dose of Havrix alone, pain was reported in 28% of subjects, redness in 22% of subjects, and swelling in 7% of subjects.


Solicited general adverse events were reported as follows among children who received the first dose of Havrix coadministered with pneumococcal 7-valent conjugate vaccine: Irritability was reported in 35% of subjects, drowsiness in 26% of subjects, loss of appetite in 25% of subjects, and fever in 14% of subjects. Reported rates of these general adverse events were similar to those in children who received the first dose of pneumococcal 7-valent conjugate vaccine alone (41%, 32%, 25%, and 16%, respectively). Among children who received the first dose of Havrix alone, irritability was reported in 35% of subjects, drowsiness in 29% of subjects, loss of appetite in 26% of subjects, and fever in 9% of subjects.



Postmarketing Experience


In addition to reports in clinical trials, worldwide voluntary reports of adverse events received for Havrix since market introduction of this vaccine are listed below. This list includes serious adverse events or events which have a suspected causal connection to components of Havrix or other vaccines or drugs. Because these events are reported voluntarily from a population of uncertain size, it is not always possible to reliably estimate their frequency or establish a causal relationship to the vaccine.


Infections and Infestations: Rhinitis.


Blood and Lymphatic System Disorders: Thrombocytopenia.


Immune System Disorders: Anaphylactic reaction, anaphylactoid reaction, serum sickness–like syndrome.


Nervous System Disorders: Convulsion, dizziness, encephalopathy, Guillain-Barré syndrome, hypoesthesia, multiple sclerosis, myelitis, neuropathy, paresthesia, somnolence, syncope.


Vascular Disorders: Vasculitis.


Respiratory, Thoracic, and Mediastinal Disorders: Dyspnea.


Hepatobiliary Disorders: Hepatitis, jaundice.


Skin and Subcutaneous Tissue Disorders: Angioedema, erythema multiforme, hyperhidrosis.


Congenital, Familial, and Genetic Disorders: Congenital anomaly.


Musculoskeletal and Connective Tissue Disorders: Musculoskeletal stiffness.


General Disorders and Administration Site Conditions: Chills, influenza-like symptoms, injection site reaction, local swelling.



Drug Interactions



Concomitant Administration With Vaccines and Immune Globulin


Havrix may be given concurrently with INFANRIX (DTaP) and Hib conjugate vaccine (PRP-T) (Sanofi Pasteur SA) [see Adverse Reactions (6.1) and Clinical Studies (14.5)].


Havrix may be given concurrently with pneumococcal 7-valent conjugate vaccine (Wyeth Pharmaceuticals Inc.) [see Adverse Reactions (6.1) and Clinical Studies (14.5)].


Havrix may be administered concomitantly with immune globulin.


When concomitant administration of other vaccines or immune globulin is required, they should be given with different syringes and at different injection sites. Do not mix Havrix with any other vaccine or product in the same syringe or vial.



Immunosuppressive Therapies


Immunosuppressive therapies, including irradiation, antimetabolites, alkylating agents, cytotoxic drugs, and corticosteroids (used in greater than physiologic doses), may reduce the immune response to Havrix.



USE IN SPECIFIC POPULATIONS



Pregnancy


Pregnancy Category C


Animal reproduction studies have not been conducted with Havrix. It is also not known whether Havrix can cause fetal harm when administered to a pregnant woman or can affect reproduction capacity. Havrix should be given to a pregnant woman only if clearly needed.



Nursing Mothers


It is not known whether Havrix is excreted in human milk. Because many drugs are excreted in human milk, caution should be exercised when Havrix is administered to a nursing woman.



Pediatric Use


The safety and effectiveness of Havrix have been evaluated in 20,869 subjects 1 year to 18 years of age.


The safety and effectiveness of Havrix have not been established in subjects younger than 12 months of age.



Geriatric Use


Clinical studies of Havrix did not include sufficient numbers of subjects 65 years of age and older to determine whether they respond differently from younger subjects. Other reported clinical experience has not identified differences in overall safety between these subjects and younger adult subjects.



Hepatic Impairment


Subjects with chronic liver disease had a lower antibody response to Havrix than healthy subjects [see Clinical Studies (14.3)].



Havrix Description


Havrix (Hepatitis A Vaccine) is a sterile suspension of inactivated virus for intramuscular administration. The virus (strain HM175) is propagated in MRC-5 human diploid cells. After removal of the cell culture medium, the cells are lysed to form a suspension. This suspension is purified through ultrafiltration and gel permeation chromatography procedures. Treatment of this lysate with formalin ensures viral inactivation. Viral antigen activity is referenced to a standard using an enzyme linked immunosorbent assay (ELISA), and is therefore expressed in terms of ELISA Units (EL.U.).


Each 1-mL adult dose of vaccine contains 1440 EL.U. of viral antigen, adsorbed on 0.5 mg of aluminum as aluminum hydroxide.


Each 0.5-mL pediatric dose of vaccine contains 720 EL.U. of viral antigen, adsorbed onto 0.25 mg of aluminum as aluminum hydroxide.


Havrix contains the following excipients: Amino acid supplement (0.3% w/v) in a phosphate-buffered saline solution and polysorbate 20 (0.05 mg/mL). From the manufacturing process, Havrix also contains residual MRC-5 cellular proteins (not more than 5 mcg/mL), formalin (not more than 0.1 mg/mL), and neomycin sulfate (not more than 40 ng/mL), an aminoglycoside antibiotic included in the cell growth media.


Havrix is formulated without preservatives.


Havrix is available in vials and 2 types of prefilled syringes. One type of prefilled syringe has a tip cap which may contain natural rubber latex. The other type has a tip cap and a rubber plunger which contain dry natural latex rubber. The vial stopper does not contain latex. [See How Supplied/Storage and Handling (16).]



Havrix - Clinical Pharmacology



Mechanism of Action


The hepatitis A virus belongs to the picornavirus family. It is one of several hepatitis viruses that cause systemic disease with pathology in the liver.


The incubation period for hepatitis A averages 28 days (range: 15 to 50 days).1 The course of hepatitis A infection is extremely variable, ranging from asymptomatic infection to icteric hepatitis and death.


The presence of antibodies to HAV confers protection against hepatitis A infection. However, the lowest titer needed to confer protection has not been determined.



Nonclinical Toxicology



Carcinogenesis, Mutagenesis, Impairment of Fertility


Havrix has not been evaluated for its carcinogenic potential, mutagenic potential, or potential for impairment of fertility.



Clinical Studies



Pediatric Effectiveness Studies


Protective efficacy with Havrix has been demonstrated in a double-blind, randomized controlled study in school children (age 1 to 16 years) in Thailand who were at high risk of HAV infection. A total of 40,119 children were randomized to be vaccinated with either Havrix 360 EL.U. or ENGERIX-B at 0, 1, and 12 months. 19,037 children received a primary course (doses at 0 and 1 months) of Havrix and 19,120 children received a primary course (doses at 0 and 1 months) of ENGERIX-B. 38,157 children entered surveillance at day 138 and were observed for an additional 8 months. Using the protocol-defined endpoint (≥2 days absence from school, ALT level >45 U/mL, and a positive result in the HAVAB-M test), 32 cases of clinical hepatitis A occurred in the control group. In the Havrix group, 2 cases were identified. These 2 cases were mild in terms of both biochemical and clinical indices of hepatitis A disease. Thus the calculated efficacy rate for prevention of clinical hepatitis A was 94% (95% Confidence Interval [CI]: 74, 98).


In outbreak investigations occurring in the trial, 26 clinical cases of hepatitis A (of a total of 34 occurring in the trial) occurred. No cases occurred in vaccinees who received Havrix.


Using additional virological and serological analyses post hoc, the efficacy of Havrix was confirmed. Up to 3 additional cases of mild clinical illness may have occurred in vaccinees. Using available testing, these illnesses could neither be proven nor disproven to have been caused by HAV. By including these as cases, the calculated efficacy rate for prevention of clinical hepatitis A would be 84% (95% CI: 60, 94).


In a study designed to interrupt an epidemic of hepatitis A among Native Americans in Alaska, vaccination with a single dose of Havrix (1440 EL.U./mL in adults, 720 EL.U./0.5 mL in children and adolescents) appeared to be efficacious.



Immunogenicity in Children and Adolescents


Immune Response to Havrix 720 EL.U./0.5 mL at 11 Months of Age and Older: In a prospective, open-label, multicenter study, 1,085 children were enrolled into one of 5 groups:


(1) Children 11 to 13 months of age who received Havrix on a 0- and 6-month schedule;


(2) Children 15 to 18 months of age who received Havrix on a 0- and 6-month schedule;


(3) Children 15 to 18 months of age who received Havrix coadministered with INFANRIX and Hib conjugate vaccine (PRP-T) (Sanofi Pasteur SA) at month 0 and Havrix at month 6;


(4) Children 15 to 18 months of age who received INFANRIX coadministered with Hib conjugate vaccine (PRP-T) (Sanofi Pasteur SA) at month 0 and Havrix at months 1 and 7;


(5) Children 23 to 25 months of age who received Havrix on a 0- and 6-month schedule.


Among subjects in all groups, 52% were male; 61% of subjects were white, 9% black, 3% Asian, and 27% were of other racial groups. The anti-hepatitis A antibody vaccine responses and GMTs, calculated on responders for groups 1, 2, and 5 are presented in Table 1. Vaccine response rates were similar among the 3 age groups that received Havrix. One month after the second dose of Havrix, the GMT in each of the younger age groups (11 to 13 and 15 to 18 months of age) was shown to be similar to that achieved in the 23 to 25 months of age group.




























Table 1. Anti-Hepatitis A Immune Response Following 2 Doses of Havrix 720 EL.U./0.5 mL Administered 6 Months Apart in Children Given the First Dose of Havrix at 11 to 13 Months of Age, 15 to 18 Months of Age, or 23 to 25 Months of Age
Age groupNVaccine Response

GMT


(mIU/mL)
%95% CI   
11-13 months (Group 1)2189997, 1001,461a
15-18 months (Group 2)20010098, 1001,635a
23-25 months (Group 5)21110098, 1001,911

 Vaccine response = Seroconversion (anti-HAV ≥15 mIU/mL [lower limit of antibody measurement by assay]) in children initially seronegative or at least the maintenance of the pre-vaccination anti-HAV concentration in initially seropositive children.


CI = Confidence Interval; GMT = Geometric mean antibody titer.


aCalculated on vaccine responders one month post-dose 2. GMTs in children 11 to 13 months of age and 15 to 18 months of age were non-inferior (similar) to the GMT in children 23 to 25 months of age (i.e., the lower limit of the two-sided 95% CI on the GMT ratio for Group 1/Group 5 and for Group 2/Group 5 were both ≥0.5).


Immune Response to Havrix 360 EL.U. at 2 Years of Age and Older: In 6 clinical studies of subjects 2 to 18 years of age (n = 762) who received 2 doses of Havrix (360 EL.U.) given 1 month apart, the GMT ranged from 197 to 660 mIU/mL. Ninety-nine percent of subjects seroconverted following 2 doses. When a booster (third) dose of Havrix 360 EL.U. was administered 6 months following the initial dose, all subjects were seropositive 1 month following the booster dose, with GMTs rising to a range of 3,388 to 4,643 mIU/mL. In 1 study in which children were followed for an additional 6 months, all subjects remained seropositive.


Immune Response to Havrix 720 EL.U./0.5 mL at 2 Years of Age and Older: In 4 clinical studies, children and adolescents (n = 314), ranging from 2 to 19 years of age, were immunized with 2 doses of Havrix 720 EL.U./0.5 mL given 6 months apart. One month after the first dose, seroconversion (anti-HAV ≥20 mIU/mL [lower limit of antibody measurement by assay]) ranged from 96.8% to 100%, with GMTs of 194 mIU/mL to 305 mIU/mL. In studies in which sera were obtained 2 weeks following the initial dose, seroconversion ranged from 91.6% to 96.1%. One month following a booster dose at month 6, all subjects were seropositive, with GMTs ranging from 2,495 mIU/mL to 3,644 mIU/mL.


In an additional study in which the booster dose was delayed until 1 year following the initial dose, 95.2% of the subjects were seropositive just prior to administration of the booster dose. One month later, all subjects were seropositive, with a GMT of 2,657 mIU/mL.


Also, Havrix has been found to be efficacious in a clinical study of children at high risk of HAV infection [see Clinical Studies (14.1)].



Immunogenicity in Adults


Over 400 healthy adults 18 to 50 years of age in 3 clinical studies were given a single 1440 EL.U. dose of Havrix. All subjects were seronegative for hepatitis A antibodies at baseline. Specific humoral antibodies against HAV were elicited in more than 96% of subjects when measured 1 month after vaccination. By day 15, 80% to 98% of vaccinees had already seroconverted (anti-HAV ≥20 mIU/mL [lower limit of antibody measurement by assay]). GMTs of seroconverters ranged from 264 to 339 mIU/mL at day 15 and increased to a range of 335 to 637 mIU/mL by 1 month following vaccination.


The GMTs obtained following a single dose of Havrix are at least several times higher than that expected following receipt of immune globulin.


In a clinical study using 2.5 to 5 times the standard dose of immune globulin (standard dose = 0.02 to 0.06 mL/kg), the GMT in recipients was 146 mIU/mL at 5 days post-administration, 77 mIU/mL at month 1, and 63 mIU/mL at month 2.


In 2 clinical trials in which a booster dose of 1440 EL.U. was given 6 months following the initial dose, 100% of vaccinees (n = 269) were seropositive 1 month after the booster dose, with GMTs ranging from 3,318 mIU/mL to 5,925 mIU/mL. The titers obtained from this additional dose approximate those observed several years after natural infection.


In a subset of vaccinees (n = 89), a single dose of Havrix 1440 EL.U. elicited specific anti-HAV neutralizing antibodies in more than 94% of vaccinees when measured 1 month after vaccination. These neutralizing antibodies persisted until month 6. One hundred percent of vaccinees had neutralizing antibodies when measured 1 month after a booster dose given at month 6.


Immunogenicity of Havrix was studied in subjects with chronic liver disease of various etiologies. 189 healthy adults and 220 adults with either chronic hepatitis B (n = 46), chronic hepatitis C (n = 104), or moderate chronic liver disease of other etiology (n = 70) were vaccinated with Havrix 1440 EL.U. on a 0- and 6-month schedule. The last group consisted of alcoholic cirrhosis (n = 17), autoimmune hepatitis (n = 10), chronic hepatitis/cryptogenic cirrhosis (n = 9), hemochromatosis (n = 2), primary biliary cirrhosis (n = 15), primary sclerosing cholangitis (n = 4), and unspecified (n = 13). At each time point, geometric mean antibody titers (GMTs) were lower for subjects with chronic liver disease than for healthy subjects. At month 7, the GMTs ranged from 478 mIU/mL (chronic hepatitis C) to 1,245 mIU/mL (healthy). One month after the first dose, seroconversion rates in adults with chronic liver disease were lower than in healthy adults. However, 1 month after the booster dose at month 6, seroconversion rates were similar in all groups; rates ranged from 94.7% to 98.1%. The relevance of these data to the duration of protection afforded by Havrix is unknown.


In subjects with chronic liver disease, local injection site reactions with Havrix were similar among all 4 groups, and no serious adverse events attributed to the vaccine were reported in subjects with chronic liver disease.



Duration of Immunity


The duration of immunity following a complete schedule of immunization with Havrix has not been established.



Immune Response to Concomitantly Administered Vaccines


Concomitant Administration With INFANRIX (DTaP) and Hib Conjugate Vaccine (PRP-T):In a US multicenter randomized study, 468 subjects, children 15 months of age (range 14 to 16 months) received either Havrix coadministered with INFANRIX (DTaP) and Hib conjugate vaccine (PRP-T) (Sanofi Pasteur SA) followed by a second dose of Havrix 6 to 9 months later (n = 127); INFANRIX and Hib conjugate vaccine alone followed by a first dose of Havrix one month later and a second dose of Havrix 6 to 9 months after the first (n = 132); or Havrix administered alone followed by a second dose of Havrix 6 to 9 months later (n = 135). Children had completed a primary series of diphtheria, tetanus, acellular pertussis, and Hib conjugate vaccines.


Seropositivity to HAV was defined as anti-HAV ≥15 mIU/mL [lower limit of antibody measurement by assay]. Results of analyses of the co-primary immunogenicity endpoints are as follows: One month after the second dose of Havrix, the seropositivity rate (100%, 84/84) in those receiving the first dose of Havrix coadministered with INFANRIX and Hib conjugate vaccine was shown to be non-inferior to that achieved (100%, 88/88) in children who received Havrix alone (lower limit of 95% CI on the difference of Havrix + INFANRIX + Hib conjugate vaccine minus Havrix >-5%). One month after the second dose of Havrix, anti-HAV GMTs were 1,904 mIU/mL for Havrix coadministered with INFANRIX and Hib conjugate vaccine and 1,700 mIU/mL for Havrix alone (non-inferior based on the lower limit of 95% CI for the adjusted GMT ratio [Havrix + INFANRIX + Hib conjugate vaccine:Havrix] ≥0.5).


One month after the first dose of Havrix coadministered with INFANRIX and Hib conjugate vaccine, seroprotection rates (≥0.1 mIU/mL) for diphtheria and tetanus were non-inferior to those achieved following INFANRIX and Hib conjugate vaccine alone (lower limit of 95% CI on the difference of Havrix + INFANRIX + Hib conjugate vaccine minus INFANRIX + Hib conjugate vaccine >-10%). For each of the pertussis antigens, vaccine response rates were non-inferior to those achieved following INFANRIX and Hib conjugate vaccine alone (antibody concentrations ≥5 EL.U./mL in subjects initially seronegative or post-vaccination antibody concentration ≥2 times the pre-vaccination antibody concentration in subjects initially seropositive; lower limit of 95% CI on the difference of Havrix + INFANRIX + Hib conjugate vaccine minus INFANRIX + Hib conjugate vaccine >-10%). GMTs for antibodies against each of the pertussis antigens following Havrix coadministered with INFANRIX and Hib conjugate vaccine were non-inferior to those following INFANRIX and Hib conjugate vaccine alone (lower limit of 95% CI for the adjusted GMT ratio [Havrix + INFANRIX + Hib conjugate vaccine:INFANRIX + Hib conjugate vaccine] ≥0.66). One month after vaccination, the anti-PRP seroprotection rate (≥1 mcg/mL) following Havrix coadministered with INFANRIX and Hib conjugate vaccine (100%, 90/90) was non-inferior to that achieved following INFANRIX and Hib conjugate vaccine alone (97.5%, 79/81) (lower limit of 95% CI on the difference of Havrix + INFANRIX + Hib conjugate vaccine minus INFANRIX + Hib conjugate vaccine >-10%).


Concomitant Administration With Pneumococcal 7-Valent Conjugate Vaccine: In a US multicenter study, children 15 months of age (range 14 to 16 months) received one of 3 regimens: (Group 1) Havrix coadministered with pneumococcal 7-valent conjugate vaccine (Wyeth Pharmaceuticals Inc.) followed by a second dose of Havrix 6 to 9 months later; (Group 2) Havrix administered alone followed by a second dose of Havrix 6 to 9 months later; or (Group 3) pneumococcal 7-valent conjugate vaccine administered alone followed by a first dose of Havrix one month later and a second dose of Havrix 6 to 9 months after the first.


One month after the second dose, the anti-hepatitis A GMT of Havrix coadministered with pneumococcal 7-valent conjugate vaccine was non-inferior to Havrix given alone (Group 1 GMT = 1,518 mIU/mL; Group 2 GMT = 1,666 mIU/mL). The difference in anti-hepatitis A seropositivity rates between groups (Havrix coadministered with pneumococcal 7-valent conjugate vaccine minus Havrix alone) was marginally lower than the pre-defined non-inferiority limit of -5% (lower limit of the two-sided 95% CI -5.78%). However, in all 3 groups, the seropositivity rate ranged between 98% and 100% one month after the second dose of Havrix (Group 1, 93/94; Group 2, 106/106; Group 3, 113/115).


One month after vaccination, non-inferiority was demonstrated with respect to GMTs for anti-pneumococcal antibodies to all 7 serotypes after the coadministration of pneumococcal 7-valent conjugate vaccine with Havrix compared to pneumococcal 7-valent conjugate vaccine alone. At least 98% of subjects who received pneumococcal 7-valent conjugate vaccine coadministered with Havrix and those who received pneumococcal 7-valent conjugate vaccine alone were seropositive for all 7 pneumococcal serotypes.


There are limited data on the coadministration of Havrix with other vaccines.



REFERENCES


  1. Centers for Disease Control and Prevention. Prevention of hepatitis A through active or passive immunization: Recommendations of the Immunization Practices Advisory Committee (ACIP). MMWR 2006;55(RR-7):1-23.

  2. Centers for Disease Control and Prevention. Update: Prevention of hepatitis A after exposure to hepatitis A virus and in international travelers. Updated Recommendations of the Advisory Committee on Immunization Practices (ACIP). MMWR 2007;56(41):1080-1084.


How Supplied/Storage and Handling


Havrix is available in single-dose vials (contain no latex) and prefilled TIP-LOK syringes (may contain latex) (packaged without needles) (Preservative Free Formulation):


720 EL.U./0.5 mL


NDC 58160-825-01 Vial (contains no latex) in Package of 10: NDC 58160-825-11


NDC 58160-825-43 Syringe (tip cap may contain latex) in Package of 10: NDC 58160-825-52


NDC 58160-825-41 Syringe (tip cap and plunger contain latex) in Package of 5: NDC 58160-825-46


NDC 58160-825-41 Syringe (tip cap and plunger contain latex) in Package of 10: NDC 58160-825-51


1440 EL.U./mL


NDC 58160-826-01 Vial (contains no latex) in Package of 10: NDC 58160-826-11


NDC 58160-826-43 Syringe (tip cap may contain latex) in Package of 5: NDC 58160-826-48


NDC 58160-826-43 Syringe (tip cap may contain latex) in Package of 10: NDC 58160-826-52


NDC 58160-826-32 Syringe (tip cap and plunger contain latex) in Package of 1: NDC 58160-826-32


NDC 58160-826-41 Syringe (tip cap and plunger contain latex) in Package of 5: NDC 58160-826-46


Store refrigerated between 2° and 8°C (36° and 46°F). Do not freeze. Discard if the vaccine has been frozen. Do not dilute to administer.



Patient Counseling Information


  • Inform vaccine recipients and parents or guardians of the potential benefits and risks of immunization with Havrix.

  • Emphasize, when educating vaccine recipients and parents or guardians regarding potential side effects, that Havrix contains non-infectious killed viruses and cannot cause hepatitis A infection.

  • Instruct vaccine recipients and parents or guardians to report any adverse events to their healthcare provider.

  • Give vaccine recipients and parents or guardians the Vaccine Information Statements, which are required by the National Childhood Vaccine Injury Act of 1986 to be given prior to immunization. These materials are available free of charge at the Centers for Disease Control and Prevention (CDC) website (www.cdc.gov/vaccines).

Havrix, ENGERIX-B, INFANRIX, and TIP-LOK are registered trademarks of GlaxoSmithKline.


Manufactured by GlaxoSmithKline Biologicals


Rixensart, Belgium, US License No. 1617


Distributed by GlaxoSmithKline


Research Triangle Park, NC 27709


©2010, GlaxoSmithKline. All rights reserved.


October 2010


HVX:34PI



Principal Display Panel


NDC 58160-825-11


Havrix®


Hepatitis A Vaccine


720 EL.U./0.5mL


10 x 0.5 mL Single-Dose Vials


For Pediatric/ Adolescent Use Only


Rx only


 Store refrigerated between 2° and 8°C (36° and 46°F). Do not freeze. Discard if frozen.


Each 0.5 mL of vaccine contains 720 EL.U. of viral antigen (derived from virus strain HM175 propagated in MRC-5 human diploid cells), adsorbed on 0.25 mg of aluminum as aluminum hydroxide; amino acid supplement (0.3% w/v) in phosphate-buffered saline solution and polysorbate 20 (0.05 mg/mL); inactivated with formalin.


Contains trace amount of neomycin (not more than 20 ng/0.5 mL).


Contains no preservative.


Do not dilute; shake well before using.


For intramuscular administration only.


Contains no latex.


Dosage: 720 EL.U. (0.5 mL) equals one pediatric/adolescent dose. See complete prescribing information for vaccination schedule.


Havrix is a registered trademark of GlaxoSmithKline.


U.S. License 1617


Manufactured by


GlaxoSmithKline Biologicals,


Rixensart , Belgium


Distributed by GlaxoSmithKline,


Research Triangle Park, NC 27709


Made in Belgium


©2010, GlaxoSmithKline




Principal Display Panel


NDC 58160-826-11


Havrix®


Hepatitis A Vaccine


1440 EL.U./mL


10 x 1 mL Single-Dose Vials


For Adult Use Only


Rx only


 Store refrigerated between 2° and 8°C (36° and 46°F). Do not freeze. Discard if frozen.


Each 1 mL of vaccine contains 1440 EL.U. of viral antigen (derived from virus strain HM175 propagated in MRC-5 human diploid cells), adsorbed on 0.5 mg of aluminum as aluminum hydroxide; amino acid supplement (0.3% w/v) in phosphate-buffered saline solution and polysorbate 20 (0.05 mg/mL); inactivated with formalin.


Contains trace amount of neomycin (not more than 40 ng/mL).


Contains no preservative.


Do not dilute; shake well before using.


For intramuscular administration only.


Contains no latex.


Dosage: 1440 EL.U. (1 mL) equals one adult dose. See complete prescribing information for vaccination schedule.


Havrix is a registered trademark of GlaxoSmithKline.


U.S. License 1617


Manufactured by


GlaxoSmithKline Biologicals,


Rixensart , Belgium


Distributed by GlaxoSmithKline,


Research Triangle Park, NC 27709


Made in Belgium


©2010, GlaxoSmithKline









Havrix 
hepatitis a vaccine  injection, suspension










Product Information
Product TypeVACCINENDC Product Code (Source)58160-825
Route of AdministrationINTRAMUSCULARDEA Schedule    








Active Ingredient/Active Moiety
Ingredient NameBasis of StrengthStrength
HEPATITIS A VIRUS STRAIN HM175 ANTIGEN (FORMALDEHYDE INACTIVATED) (HEPATITIS A VIRUS STRAIN HM175 ANTIGEN (FORMALDEHYDE INACTIVATED))HEPATITIS A VIRUS STRAIN HM175 ANTIGEN (FORMALDEHYDE INACTIVATED)720 [iU]  in 0.5 mL








Inactive Ingredients
Ingredient NameStrength
ALUMINUM HYDROXIDE 
POLYSORBATE 20 


















Product Characteristics
Color    Score    
ShapeSize
FlavorImprint Code
Contains      










Packaging
#NDCPackage DescriptionMultilevel Packaging
158160-825-465 SYRINGE In 1 CARTONcontains a SYRINGE

Wednesday, 28 December 2011

Phenolurn




Phenolurn may be available in the countries listed below.


Ingredient matches for Phenolurn



Tamoxifen

Tamoxifen citrate (a derivative of Tamoxifen) is reported as an ingredient of Phenolurn in the following countries:


  • Japan

International Drug Name Search